<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674294</url>
  </required_header>
  <id_info>
    <org_study_id>Aprepitant-CINV</org_study_id>
    <nct_id>NCT03674294</nct_id>
  </id_info>
  <brief_title>Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy</brief_title>
  <acronym>CINV</acronym>
  <official_title>Sun Yat-sen University Cancer Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study whether adding Aprepitant to Palonosetron and&#xD;
      dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by&#xD;
      FOLFIRI or FOLFOX chemotherapy regimen among gastrointestinal malignancy patients with high&#xD;
      risk factors of chemotherapy-associated adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to study whether adding Aprepitant to Palonosetron and&#xD;
      dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by&#xD;
      FOLFIRI or FOLFOX chemotherapy regimen after curative effect among gastrointestinal&#xD;
      malignancy patients with high risk factors of chemotherapy-associated adverse events.This&#xD;
      study will observe and evaluate the incidence and severity of nausea and vomiting as well as&#xD;
      the effectiveness of corresponding treatment(with or without Aprepitant) during Day 1 to Day&#xD;
      5 from the beginning of chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2015</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate during the overall phase</measure>
    <time_frame>Up to 1-2 months</time_frame>
    <description>The proportion of patients without emesis episodes or rescue medication use during the overall phase (0-120 h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate in the acute phase</measure>
    <time_frame>Up to 1-2 months</time_frame>
    <description>The proportion of patients without emesis episodes or rescue medication use during the acute phase (0-24h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate in the delayed phase</measure>
    <time_frame>Up to 1-2 months</time_frame>
    <description>The proportion of patients without emesis episodes or rescue medication use during the delayed phase (25-120 h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No vomiting rate in the acute phase, delayed phase and overall phase</measure>
    <time_frame>Up to 1-2 months</time_frame>
    <description>The proportion of no vomiting (no vomiting or retching episodes) in the acute phase, delayed phase and overall phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affection caused by CINV reported by patients</measure>
    <time_frame>Up to 1-2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CINV on daily life</measure>
    <time_frame>Up to 1-2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Palonosetron/Dexamethasone/Aprepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Palonosetron/Dexamethasone/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Aprepitant is manufactured by Merck &amp; Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003</description>
    <arm_group_label>Palonosetron/Dexamethasone/Aprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.</description>
    <arm_group_label>Palonosetron/Dexamethasone/Aprepitant</arm_group_label>
    <arm_group_label>Palonosetron/Dexamethasone/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.</description>
    <arm_group_label>Palonosetron/Dexamethasone/Aprepitant</arm_group_label>
    <arm_group_label>Palonosetron/Dexamethasone/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.</description>
    <arm_group_label>Palonosetron/Dexamethasone/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed by pathology as gastrointestinal carcinoma and no previous FOLFOX or FOLFIRI&#xD;
             based regimen chemotherapy history.&#xD;
&#xD;
          -  Female.&#xD;
&#xD;
          -  Adult patients ( ≥ 18, ≤ 50 years of age)&#xD;
&#xD;
          -  No long-term or excessive alcohol intake history:1.Alcohol intake less than 5 times&#xD;
             per week; 2.Alcohol intake less than 100g per day.&#xD;
&#xD;
          -  Performance status ECOG 0-1&#xD;
&#xD;
          -  Adequate haematological, hepatic, renal and metabolic function parameters:&#xD;
&#xD;
        Leukocytes : 3,500-10,000/mm3, ANC ≥ 1,500/mm3, Platelets ≥ 90,000/mm3, Hb &gt; 9g/dl (may be&#xD;
        transfused or treated with erythropoietin to maintain or exceed this level), Serum&#xD;
        creatinine ≤ 1 x upper limit of normal, Bilirubin ≤ 1.5 x upper limit of normal, Serum AST,&#xD;
        ALT, ALP ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit&#xD;
        of normal in presence of liver metastases.&#xD;
&#xD;
          -  Negative pregnancy test. If pregnancy test were positive, subject should be included&#xD;
             in the trial only when the subsequent pregnancy test is negative.&#xD;
&#xD;
          -  Ability of reading, comprehending and finishing trial questionnaires and record,&#xD;
             including VAS (Visual Analogue Scale) question.&#xD;
&#xD;
          -  Before subject registration, written informed consent must be given according to local&#xD;
             regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women without morning sickness.&#xD;
&#xD;
          -  Presence of gastrointestinal tract obstruction or electrolyte imbalance.&#xD;
&#xD;
          -  Any history of central nervous system disease(e.g. Primary brain tumour, seizure not&#xD;
             controlled with standard medical therapy, brain metastases or history of stroke).&#xD;
&#xD;
          -  Contraindication of glucocorticoid:1.Infection of virus, bacteria or fungus&#xD;
             uncontrolled by antibiotics; 2.Active stomach or duodenum ulcer; 3.Severe&#xD;
             hypertension, atherosclerosis, diabetes; 4.Osteoporosis;5.Corneal ulcer; 6.Pregnancy;&#xD;
             7.Reparative phase of trauma, operation or fraction; 8.Hypercortisolism; 9.Severe&#xD;
             mental disorder or epilepsy; 10.Inadequate cardiac or renal function.&#xD;
&#xD;
          -  Mental disability or severe emotional or mental disorder.&#xD;
&#xD;
          -  Active infection(e.g. pneumonia, hepatitis) or any uncontrolled disease(e.g.diabetic&#xD;
             ketoacidosis) that may affect study outcome or expose patients to unnecessary risk.&#xD;
&#xD;
          -  Usage of any illicit drug, including medical marijuana or alcohol abusing(China drug&#xD;
             dependence criteria).&#xD;
&#xD;
          -  Treatment of unapproved medicine in the previous 4 weeks.&#xD;
&#xD;
          -  Concomitant therapy of psychotropic medicine such as olanzapine.&#xD;
&#xD;
          -  Hypersensitivity history towards Aprepitant, 5-HT3 receptor antagonist or&#xD;
             dexamethasone.&#xD;
&#xD;
          -  Previous treatment of Aprepitant.&#xD;
&#xD;
          -  Unable to swallow capsules.&#xD;
&#xD;
          -  Main researchers considered that the patient is unsuited to the trial.&#xD;
&#xD;
          -  Unable or unwilling to follow research programme.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>Director, Department of Medical Oncology, Principal Investigator, Clinical Professor, Yuhong Li</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

